171 related articles for article (PubMed ID: 16418689)
1. Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics?
Burckart GJ; Liu XI
Ther Drug Monit; 2006 Feb; 28(1):23-30. PubMed ID: 16418689
[TBL] [Abstract][Full Text] [Related]
2. [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].
Fukudo M
Yakugaku Zasshi; 2007 Jul; 127(7):1081-9. PubMed ID: 17603267
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.
Provenzani A; Santeusanio A; Mathis E; Notarbartolo M; Labbozzetta M; Poma P; Provenzani A; Polidori C; Vizzini G; Polidori P; D'Alessandro N
World J Gastroenterol; 2013 Dec; 19(48):9156-73. PubMed ID: 24409044
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
5. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation.
Zhao W; Fakhoury M; Jacqz-Aigrain E
Ther Drug Monit; 2010 Dec; 32(6):688-99. PubMed ID: 21068645
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
7. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
8. The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration.
Fredericks S; Holt DW; MacPhee IA
Am J Pharmacogenomics; 2003; 3(5):291-301. PubMed ID: 14575518
[TBL] [Abstract][Full Text] [Related]
9. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.
Utecht KN; Hiles JJ; Kolesar J
Am J Health Syst Pharm; 2006 Dec; 63(23):2340-8. PubMed ID: 17106006
[TBL] [Abstract][Full Text] [Related]
10. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
12. Use of pharmacogenetics to optimize immunosuppressive therapy.
Macphee IA
Ther Drug Monit; 2010 Jun; 32(3):261-4. PubMed ID: 20431509
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.
Picard N; Bergan S; Marquet P; van Gelder T; Wallemacq P; Hesselink DA; Haufroid V
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S57-69. PubMed ID: 26469711
[TBL] [Abstract][Full Text] [Related]
14. "What do we know about tacrolimus pharmacogenetics in transplant recipients?".
Kuypers DR
Pharmacogenomics; 2018 May; 19(7):593-597. PubMed ID: 29701126
[No Abstract] [Full Text] [Related]
15. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
[TBL] [Abstract][Full Text] [Related]
16. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
Gervasini G; Garcia M; Macias RM; Cubero JJ; Caravaca F; Benitez J
Transpl Int; 2012 Apr; 25(4):471-80. PubMed ID: 22369694
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises.
Cattaneo D; Baldelli S; Perico N
Am J Transplant; 2008 Jul; 8(7):1374-83. PubMed ID: 18510642
[TBL] [Abstract][Full Text] [Related]
19. PharmGKB summary: cyclosporine and tacrolimus pathways.
Barbarino JM; Staatz CE; Venkataramanan R; Klein TE; Altman RB
Pharmacogenet Genomics; 2013 Oct; 23(10):563-85. PubMed ID: 23922006
[No Abstract] [Full Text] [Related]
20. Influence of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics/Pharmacodynamics of Tacrolimus in Pediatric Patients.
Yang M; Huan G; Wang M
Curr Drug Metab; 2018; 19(14):1141-1151. PubMed ID: 30251601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
